Urothelial tumors;Tumeurs urothéliales

Progres en Urologie

Volumn 17, Issue 6, 2007, Pages 1063-1098

  Irani, Jacques ^a   Bernardini, Stéphane ^a   Bonnal, Jean Louis ^a   Chauvet, Bruno ^a   Colombel, Marc ^a   Davin, Jean Louis ^a   Laurent, Guy ^a   Lebret, Thierry ^a   Maidenberg, Marc ^a   Mazerolles, Catherine ^a   Pfister, Christian ^a   Roupret, Morgan ^a   Roy, Catherine ^a   Rozet, François ^a   Saint, Fabien ^a   Theodore, Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INVASION; CLASSIFICATION; ECHOGRAPHY; ENDOSCOPY; HUMAN; METASTASIS; PATHOLOGY; URINARY TRACT CANCER; UROTHELIUM;

ENDOSCOPY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; ULTRASONOGRAPHY; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 40749148118     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (324)

1. AJCC Cancer Staging Manual. 6th edition. Springer 2002.
2. Wittekind et al TNM classification UICC 2005. Spinger Verlab Eds.
3. COOKSON MS, HERR HW, ZHANG ZF, SOLOWAY S, SOGANI P, FAIR W. The treated natural history of high-risk superficial bladder cancer: 15-year outcome. J. Urol. 1997; 158: 62-67.
4. MANSSON A, ANDERSON H, COLLEEN S. Time lag to diagnosis of bladder cancer : influence of psychosocial parameters and level of health-care provision. Scand. J. Urol. Nephrol. 1993; 27 : 363-365.
5. GATTEGNO B, CHOPIN D. Rapport 2001 de l'Association Française d'Urologie. Prog. Urol. 2001; 11(5): 993-1019.
6. CUMMINGS KB, BARONE JG, WARD WS. Diagnosis and stagging of bladder cancer. Urol. Clin. North Am. 1992; 19: 455-465.
7. ZINCKE H, UTZ DC, FARROW GM. Review of Mayo Clinic with carcinoma in situ. Urology 1985; 26(4): 39-46.
8. WITJES JA. Bladder carcinoma in situ in 2003 : State of the art. Eur. Urol. 2004; 45(2): 142-146.
9. MOHR DN, OFFORD KP, OWEN RA, MELTON LJ. Asymptomatic microhematuria and urologic disease. A population-based study. JAMA 1986; 256(2): 224-229.
10. MAYFIELD MP, WHELAN P. Bladder tumors detected on screening : results at 7 years. Br. J. Urol. 1998; 82(6): 825-828.
11. DONNAT SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol. Clin. North Am. 2003; 30(4): 765-776.
12. ZHANG Z, SARKIS A, CORDON-CARDO C, DALBANI D, MELAMED J, APRIKIAN A, POLLACK D, SHEINFELD J, HERR H, FAIR W. Tobacco smoking, occupation and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol. Biomarkers Prev. 1994; 3: 19-24.
13. VINEIS P, SIMONATO L. Proportion of lung and bladder cancers in males resulting from occupation : a systematic approach. Arch. Environ Health 1991; 46:6-15.
14. BERGERET A, NORMAND J. Chemical induced cancers. Rev. Prat. 2000; 50: 391-395.
15. HEMSTREET GP, YIN S, MA Z, BONNER RB, Bi W, RAO JY, ZANG M, ZHENG Q, BANE B, ASAL N, LI G, FENG, HURST RE, WANG W. Biomarker risk assessement and bladder cancer detection in a cohort exposed to benzidine. J. Natl. Cancer Inst. 2001; 93(6): 427-436.
16. AUDUREAU E, KARMALY M, DAIGURANDE C, PARIS C, EVREUX E, THIELLY P, PFISTER C; Cancer de vessie et origine professionnelle: une analyse descriptive en Haute-Normandie en 2003. Prog. Urol. 2007; 17(2): 213-218.
17. DROLLER MJ. Markers in bladder cancer - issues to consider. J. Urol. 1998; 160(6): 2009-2010.
18. LOKESHWAR VB, SOLOWAY MS. Current bladder tumor tests : does their projected utility fulfill clinical necessity ? J. Urol. 2001; 165(4): 1067-1077.
19. JICHLINSKI P. New diagnostic strategies in the detection and staging of bladder cancer. Curr. Opin. Urol. 2003; 13(5): 351-355.
20. SIMON MA, LOKESHWAR VB, SOLOWAY MS. Review : Current bladder cancer tests : unnecessary or beneficial? Crit. Rev. Oncol. Hematol. 2003; 47(2): 91-107.
21. BROWN FM. Urine cytology. Is it still the gold standard for screening ? Urol. Clin. N. Am. 2000; 275(1): 25-37.
22. PFISTER C, CHAUTARD D, DEVONEC M, PERRIN P, CHOPIN D, RISCHMANN P, BOUCHOT O, BEURTON D, COULANGE C, RAMBEAUD JJ. Immunocyt test improves the diagnostic accuracy of urinary cytology : results of a french multicentric study. J. Urol. 2003; 169(3): 921-924.
23. TOMA MI, FRIEDRICH MG, HAUTMANN SH, JAKEL KT, ERBERS-DOBLER A, HELLSTERN A, HULAND H. Comparison of the Immunocyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J. Urol. 2004; 22(2): 145-149.
24. LOKESHWAR VB, HABUCHI T, GROSSMAN HB, MURPHY WM, HAUTMANN SH, HEMSTREET GP 3rd, BONO AV, GETZENBERG RH, GOEBELL P, SCHMITZ-DRAGER BJ, SCHALKEN JA, FRADET Y, MARBERGER M, MESSING E? DROLLER MJ: Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005; 66: 35-63.
25. RO JY, STAERKEL GA, AYALA AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am. 1992;19(3):435-53.
26. BASTACKY S, IBRAHIM S, WILCZYNSKI SP, MURPHY WM. The accuracy of urinary cytology in daily practice. Cancer. 1999:87(3): 118-28.
27. JUNKER K, FRITSCH T, HARTMANN A, SCHULZE W. SCHUBERT J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genom Res 2006; 114(3-4):279-83.
28. VAN RHIJN BW, SMITM, van GEENEN D, WIJNM AALEN A, KIRKELS WJ, VAN DER KWAST TH, KUENEN-BOUMEESTER V, ZWARTHOFF EC. Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy. Eur Urol. 2003;43(4):369-73.
29. PIATON E, DANIEL L, VERRIELE V, DALIFARD I, ZIMMERMANN U, RENAUDIN K, GOBET F, CARATERO A, DESVAUX D, POUILLE Y, SEIGNEURIN D. Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study. Lab Invest. 2003;83(6):845-52.
30. FRIEDRICH MG, HELLSTERN A, TOMA MI, HAMMERER P, HULAND H. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? Eur Urol. 2003:43(2): 146-50; discussion 150-1.
31. BROWN FM. Urine cytology. Is it still the gold standard for screening ? Urol. Clin. N. Am. 2000; 275(1): 25-37.
32. GOESSL C, KNISPEL HH, MILLER K, MAGNUSSON A. Is routine excretory urography necessary at first diagnosis of bladder cancer ? . J Urol 1997, 157:480-1.
33. SCHREYER HH, UGGOWITZER MM, RUPPERT-KOHLMAYR A. Helical CT of the urinary organs. Eur Radiol, 2002, 12 : 575-91
34. KEMPER J, ADAM G, NOLTE-ERNSTING C. Moderne diagnostic assessement of the upper urinary tract using multislice CT urography.ROFO, 2006; 178: 1086-84
35. NOLTE-ERNSTING C, COWAN N. Understanding multisclice CTurography techniques: Many roads lead to Rome. Eur Radiol. 2006 ; 16 : 2670-86
36. DALLA PALMA L, MORRA A, GROTTO M. CT Urography. Radiol Med 2005; 110: 170-8
37. TSILI A. C, ELFREDMIDIS S. C, KALEF-EZRA J, GLANNAKIS D, ALAMAMOS Y, SOFIKITIS N, TSAMPOULAS C. Multi-Detector row CT urography on a 16-row CT
38. DATTA SN, ALLEN GM, EVANS R, VAUGHTON KC, LUCAS MG. Urinary tract ultrasonography in the evaluation of haematuria a revue over 1,000 cases. Ann R Coll Surg Engl 2002 ; 84 : 203-5
39. HERRANZ-AMO F, DIEZ-CORDERO JM, VERDU-TARTAJO F, BUENO-CHOMON G, LEAL-HERNANDEZ A, BIELSA-CARRILLO A. Need for intravenous urography inpatients with rimary transitional carcinoma of the bladder ? Eur Urol, 1999, 36 : 221-24
40. SPEELMAN HR, KESSELS AG, BONGAERTS AH, DELAERE KP, DE KORTE PJ, VAN ENGELSHOM VH. Haematuria : intravenous urography, ultrasound or both ? Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr, 1996, 165: 424-28
41. SPEELMANN HR, ASLAKSEN A, HALVORSEN OJ, GÖTHLIN JH. Detection of renal and renal pelvic tumours with urography and ultrasonography. Eur Radiol 1990 ; 11 : 54-8
42. MONZON JA, FERNANDEZ GOMEZ JM, RODRIGUEZ GJ, RODRIGUEZ FO, MARTINEZ JJ, REGADERA SEJAS J. Utility of computerized tomography in determining the extent of inferior bladder tumors : our experience. Arch Esp Urol, 2003, 56 : 133-38
43. PAIK ML, SCOLIERI MJ, BROWN SL, SPIRNAK JP, RESNICK MI. Limitations of computerized tomography in staging invasive bladder before radical cystectomy. J Urol, 2000, 163 : 1693-96
44. VINNICOMBE SJ, NORMAN AR, NICOLSON V, HUSBAND JE. Normal pelviclymph nodes : evaluation with CT after bipedal lymphangiography. Radiology, 1995, 194 : 349-355
45. WOLFF SJ, CHER M, DALLA'ERA M, PREST JC. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol, 1995, 153 : 993-999.
46. BUSZELLO H, MULLER-MATTHEIS V, ACKERMANN R. Value of computerized tomography in detection of lymph node metastasis bladder cancer. Urologe, 1994, 33 : 243-46
47. EAU guidelines on bladder cancer. 2007.
48. GATTEGNO B, CHOPIN D. Tumeurs Superficielles de la Vessie. Rapport 2001 de l'Association Française d'Urologie. Prog. Urol. 2001; 11(5): 1021-1030.
49. Recommandations 2004 du CCAFU : tumeurs urothélials. Prog. Urol. 2004; 14(4 supplément no1) : 961-964.
50. SYLVESTER R, VAN DER MEEIJDEN AP, OOSTERLINK W, WITJES JA, BOUFFIOUX C, DENIS L, NEWLING DW, KURTH K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006 ; 49(3) : 466-477.
51. PARMAR, M.K.B., FREEDMAN, L.S., HARGREAVE, TB., and TOLLEY, D.A. Pronostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder cancer (Urological Cancer working Party). J. Urol., 142: 284-288, 1989.
52. READING, J., HALL, R.R., and PARMAR, M.K.B. The application of a pronostic factor analysis for Ta-T1 bladder cancer in routine urological practise. Br. J. Urol., 81: 692-698, 1998.
53. SCHMIDBAUER J, WITJES F, SCHMELLER N, DONAT R, SUSANI M, MARBERGER M. Hexvix PCB301/01 Study. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J. Urol. 2004;171(1):135-8
54. JOCHAM D, WITJES F, WAGNER S, ZEYEMAKER B, VAN MOORSELAR J, GRIMM MO, MUSCHTER R, POPKEN G, KÖNIG F, KNÜCHEL R, KURTH KH. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J. Urol. 2005; 174(3): 862-6.
55. ZERBIB M, BOUCHOT O. Les Traitements des Tumeurs Infiltrantes de Vessie. Rapport 2002 de l'Association Française d'Urologie. Prog Urol. 12(5) : 769-772.
56. BOSTWICK DG, RAMNANI D, CHENG L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am. 1999;26(3):493-507.
57. LOPEZ-BELTRAN A, BASSIP, PAVONE-MACALUSO M, MONTIRONI R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol. 2004;45(3):257-66. 56. EPSTEIN JI, AMIN MB, REUTER VR, MOSTOFI FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22(12):1435-48.
58. BILLEREY C, SIBONY M. [So-called «superficial» bladder tumors. Which classification in 2003? Part 1: Papillary tumors']. Ann Pathol. 2003;23(1):21-33.
59. EBLE JN, SAUTER G, EPSTEIN JI, SESTERHENN I. World Health Organisation classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon :IARC Press; 2004
60. SAMARATUNGA H, MAKAROV DV, EPSTEIN JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology. 2002;60(2):315-9.
61. MURPHY WM, TAKEZAWA K, MARUNIAK NA. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol. 2002;168(3):968-72.
62. FUJII Y, KAWAKAMI S, KOGA F, NEMOTO T, KIHARA K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int. 2003;92(6):559-62.
63. YIN H, LEONG AS. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol. 2004;121(5):679-87.
64. GONUL II, POYRAZ A, UNSAL C, ASCAR C, ALKIBAY T. Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urol Int 2007;78(4):338-44.
65. LOPEZ- BELTRAN A, CHENG L. Histologic variants of urothélial carcinoma: differential diagnosis and clinical implications. Hum Pathol 2006 ;37:1371-1388.
66. ANGULO JC, LOPEZ JI, GRIGNON DJ, SANCHEZ-CHAPADO M. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology. 1995;45(1):47-53.
67. HOLMANG S, HEDELIN H, ANDERSTROM C, HOLMBERG E, JOHANSSON SL. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol. 1997;157(3):800-3; discussion 804.
68. GEERDSEN J. Tumours of the renal pelvis and ureter. Symptomatology, diagnosis, treatment and prognosis. Scand J Urol Nephrol 1979;13(3):287.
69. BRETHEAU D, LECHEVALLIER E, UZAN E, et al. Value of radiologic examinations in the diagnosis and staging of upper urinary tract tumors. Prog Urol 1994;4(6):966
70. MILLÁN-RODRIGUEZ F, PALOU J, DE LA TORRE-HOLGUERA P, et al. Conventional CT signs in staging of transitional cell tumors of the upper urinary tract. Eur Urol 1999; 35(4):318
71. BATATA MA, WHITMORE WF Jr, HILARIS BS. Primary carcinoma of the ureter: a prognostic study. Cancer 1975;35(6):1626.
72. GILL WB, LU CT, THOMSEN S. Retrograde brushing: a new technique for obtaining histologic and cytologic material from ureteral, renal pelvic and renal calyceal lesions. J Urol 1973;109(4):573.
73. ZAMAN SS, SACK MJ, RAMCHANDANIP, et al. Cytopathology of retrograde renal pelvis brush specimens: an analysis of 40 cases with emphasis on collecting duct carcinoma and low-intermediate grade transitional cell carcinoma. Diagn Cytopathol 1996;15(4):312.
74. BOORJIAN S., NG C., MUNVER R., PALESE M.A., VAUGHAN E.D., JR., SOSA R.E., et al.: Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. Urology, 2005, 66: 283-7.
75. SODERDALH DW, FABRIZIO MD, RAHMAN NU, JARRETT TW, BAGLEY DH. Endoscopic treatment of upper tract transitional cell carcinoma. Urol Oncol. 2005:23(2):114-22.
76. KRAMBECK AE, THOMPSON RH, LOHSE CM, PATTERSON DE, SEGURA JW, ZINCKE H, ELLIOTT DS, BLUTE ML. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J Urol. 2007;177(5):1721-6.
77. KIEMENEY L.A., WITJES J.A., HEJBROEK R.P., KOPER N.P, VERBEEK A.L., DEBRUYNE F.M. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South East Co Operative Urological Group. Br. J. Urol., 1994; 73: 164-71.
78. VAN DER MEIJDEN A, SYLVESTER R, COLLETTE L, BONO A, AND TEN KATE. The role and impact of pathology review on stage and grade assessment of stage Ta and T1 bladder tumor : a combined analysis of 5 european organization for research and treatment of cancer trials. J. Urol., 2000: 164: 1533-7
79. BRAUERS A, BUETTNER R, AND JAKSE G. Second resection and prognosis of primary high risk superficial bladder cancer : is cystectomy often too early? J. Urol. 2001, 165: 808-10.
80. HERR HW., The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol., 1999; 162: 74-6.
81. KOYA MP , SIMON MA, SOLOWAY MS.Complication of intravesical therapy for urothelial cancer of the bladder.J.UROL. 2006, 175 (6): 2004-10.Review
82. KAASINEN E, RINTALA E, PERE AK, KALLIO J, PUOLAKKA VM, LIUKKONEN T, TUHKANEN K. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. J. Urol., 2000; 164: 47-52.
83. AU JL, BADALAMENT RA, WIENTJES MG, YOUNG DC, WARNER JA, VENEMA PL, POLLIFRONE DL, HARBRECHT JD, CHIN JL, LERNER SP, MILES BJ. International Mitomycin C Consortium, Methods to improve efficacy of intravesical mitomycin C- Result of a randomised phase III trial. J. Natl. Cancer Inst., 2001; 93: 597-604.
84. THRASHER JB, CRAWFORD ED. Urol. Clin. North Am., 1992; 19: 529-39.
85. TOLLEY D.A., PARMA M.K.B., GROGOR K.M., LALLEMAND G. and the Medical Research Council Superficial Bladder Cancer Working Party. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer : a further report with 7 years of follow-up. J. Urol., 1996; 155, 1233-1238.
86. BOUFFIOUX C, KURTH KH, BONO A, OOSTERLINK W, KRUGER CB, DE PAUW M, SYLVESTER R. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma,: result of 2 European Organization for Research and Treatment of Cancer randomised trial with mitomycin C and doxorubicin comparing early versus delayed instillations and short term versus long term treatment. J. Urol., 1995; 153: 934-41.
87. HUNCHAREK M, KUPELNICK B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitionnal cell carcinoma of the bladder: metanalytic reevaluation. Am. J. Clin. Oncol., 2003, 26(4): 402-7.
88. FRIEDRICH MG, PICHLMEIER U, SCHWAIBOLD H; CONRAD S, HULAND H. Long-termadjuvant chemotherapy further reduces recurrence rate compared with short-term intavesical chemotherapy and short term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur. Urol., 2007.
89. PAULSON D. Critical review of radical cystectomy and indicators of prognosis. Semin. Urol., 1993; 11: 205-213.
90. DALBAGNI G, HERR H.W, REUTER V.E. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology., 2002; 60: 822-825.
91. DUTTA S.C, SMITH J.A, SHAPPELL S.B, COFFEY C.S, CHANG S.S, COOKSON M.S. Clinical understaging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J. Urol., 2001; 166: 490-493.
92. HERR H.W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus calmette-guerin therapy. J. Urol., 2005; 174: 2134-2137.
93. CHOPIN D, SAINT F, GATEGNO B. Immunothérapie endovésicale : le Bacille de Calmette-Guérin. Prog. Urol., 2001; 11: 1065-1115.
94. BADALAMENT R.A, HERR H.W, WONG G.Y, GNECCO C, PINSKY C.M, WHITMORE W.F, FAIR W.R, OETTGEN H.F. A prospective randomised trial of maintenance versus nonmaintenance intravesical Bacille Calmette-Guérin therapy of superficial bladder cancer. J. Clin. Oncol., 1987; 5: 441-449.
95. LAMM DL, BLUMENSTEIN BA, CRISSMAN JD, MONTIE JE, GOTTESMAN JE, LOWE BA, SAROSDY MF, BOHL RD, GROSSMAN HB, BECK TM, LEIMERT JT, CRAWFORD ED. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124-9.
96. SAINT F, IRANI J, PATARD J.J, SALOMON L, HOZNEK A, ZAMMATTIO S, DEBOIS H, ABBOU C.C, CHOPIN D.K. Tolerability of Bacillus Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology., 2001; 57: 883-888.
97. PAGANO F, BASSI P, PIAZZA N, ABATANGELO G, DRAGO FERRANTE G.L, MILANI C. Improving the efficacy of BCG imunotherapy by dose reduction, Eur. Urol., 1995; 27: 19-22.
98. MACK D, FRICK J. Low-dose Bacillus Calmette-Guérin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada. Br. J. Urol., 1995; 75: 185-187.
99. LOSA A, HURLE R, LEMBO A. A. Low-dose Bacillus Calmette-Guérin for carcinoma in situ of the bladder: long-term results. J. Urol., 2000; 163: 68-72.
100. LEBRET T, BOHIN D, KASSARDJIAN Z, HERVE J.M, MOLINIE V, BARRE P, LUGAGNE P.M, BOTTO H. Recurrence, progression and success in stage Ta Grade 3 bladder tumors treated with low dose bacillus Calmette-Guérin instillations. J. Urol., 2000; 163: 63-67.
101. MARTINEZ-PINEIRO J.A, FLORES N, ISORNA S, SOLSONA E, SEBASTIAN J.L, PERTUSA C, RIOJA L.A, MARTINEZ-PINEIRO L, VELA R, CAMACHO J.E, NOGUEIRA J.L, PEREIRA I, RESEL L, MUNTANOLA P, GALVIS F, CHESA N, de TORRES J.A, CARBALLIDO J, BERNUY C, ARRIBAS S, MADERO R. Long-term follow-up of a randomised prospective trial comparing a standard 81 mg dose of intravesical Bacille Calmette-Guérin with a reduced dose of 27mg in superficial bladder cancer, B.J.U. Int., 2002; 89: 671-680.
102. MACK D, HÖLTL W, BASSI P, BRAUSI M, FERRARI P, de BALIN-COURT C, SYLVESTER R. The ablative effect of a quarter dose Bacillus Calmette- Guérin on a papillary marker lesion of the bladder. J. Urol., 2001; 165: 401-403.
103. VEGT P.D.J, Van der MEIJDEN A.P.M, SYLVESTER R, BRAUSSI M, HOLTL W, de BALINCOURT C. Does isoniazid reduce side effects of intravesical Bacillus Calmette-Guérin therapy in superficial bladder cancer? interim results of European Organization for Research and Treatment of Cancer protocol 30911. J. Urol., 1997; 157: 1246-1249.
104. COLOMBEL M, SAINT F, CHOPIN D, MALAVAUD B, NICOLAS L, RISCHMANN P. the effect of ofloxacine on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J. Urol., 2006; 176: 935-939.
105. BONNAL JL. Impact pratique des données pharmacologiques et cliniques de l'instillation post-opératoire précoce de mitomycine C. Prog Urol, 2002; 12: 118-123
106. WELDON T., SOLOWAY M.S. Susceptibility of urothelium to neoplastic cellular implantation. Urology, 1975; 5, 824-826.
107. WIENTJES M.G., BADALAMENT R.A., AU J.L.S. Use of pharmacologic data and computer simulations to design efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemo. Pharma., 1993; 32, 255-262.
108. WIENTJES M.G., BADALAMENT R.A., WANG R.C., HASSAN F., AU J.L.S. Penetration of Mitomicyne C in human Bladder, Cancer Res., 1993, 53, 3314-3320.
109. KAASINEN E., RINTALA E., HELLSTROM P., VITTANEN J., JUUSELA H., RAJAL A P., KORHONEN H., LIUKKONEN T. The Finladder Group. The significance of perioperative mitomycin C instillation in frequently recurrent superficial bladder carcinoma. Eur. Urol., 2000; 37, Suppl. 2, 111.
110. TRAXER O, GATTEGNO B. Early postoperative mitomycin C instillation: when and how? Prog Urol,. 2004; 14(2):249-51
111. SYLVESTER RJ, OOSTERLINCK W, VAN DER MEIJDEN AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol., 2004;171(6 Pt 1):2186-90
112. SOLSONA E., IBORRA I., RICOS J.V., MONROS J.L., CASANOVA J., DUMONT R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer : short and long term follow-up. J. Urol., 1999; 161, 1120-1123.
113. OOSTERLINCK W, LOBEL B, JAKSE G, MALMSTRÖM P.U, STÖCKLE M, STERNBERG C Guideline on bladder Cancer. Eur. Urol., 2002; 41: 105-112.
114. BÖHLE A, P.R BOCK. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology., 2004; 63: 682-7.
115. SHELLEY MD, COURT JB. KYNASTON H, WILT TJ, FISH RG, MASON M. Intravesical Bacillus Calmette-Guerin in Ta and Tl Bladder Cancer. Cochrane Database Syst Rev. 2000;(4):CD001986.
116. SYLVESTER R.J, ADRIAN PM, Van der MEIJDEN, LAMM D.L. Intravesical Bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomised clinical trials. J. Urol., 2002; 168: 1964-70.
117. BÖHLE A, JOCHAM D, BOCK P.R. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol., 2003; 169: 90-95.
118. WITJES J.A, Van der MEIJDEN A.P.M, COLLETTE L, SYLVESTER R, DEBRUYNE F.M.J, Van AUBEL A, WITJES W.P.J, Long-term follow-up of an EORTC randomized prospective trial comparing intravesical Bacille Calmette-Guérin-RIVM and Mitomycin C in superficial bladder cancer. Urology., 1998; 52: 403-410.
119. STEINBERG G, BAHNSON R, BROSMAN S, MIDDLETON R, WAJSMAN Z, WEHLE M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. J. Urol., 2000; 163: 761.
120. SAROSDY M.F, MANYAK M.J, SAGALOWSKY A.I, BELLDEGRUN A, BENSON M.C, BIHRLE W, CARROLL PR, ELLIS W.J, HUDSON M.A. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical Bacillus Calmette-Guérin. Urology., 1998; 51:226.
121. KLEIN E.A, ROGATKO A, HERR H.W. Management of local bacillus Calmette-Guérin failures in superficial bladder cancer. J. Urol., 1992; 144: 658.
122. O'DONNELL M.A, KROHN J, DeWOLF W.C. Salvage intravesical therapy with interferon-a2B plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed. J, Urol., 2001; 166: 1300-1304.
123. HERR H.W, BADALAMENT R.A, AMATO D.A, LAUDONE VP, FAIR W.R, WHITMORE W.F. Superficial bladder cancer treated with Bacillus Calmette-Guérin: a multivariate analysis of factors affecting tumor progression. J. Urol., 1989; 141: 22-29.
124. SOLSONA E, IBORRA I, DUMONT R, RUBIO-BRIONES J, CASANOVA J, ALMENAR S. The 3-month clinical response to intravesical therapy as predictive factor for progression in patients with hight risk superficial bladder cancer. J. Urol., 2000; 164: 685-9.
125. ORSOLAA, PALOU J, XAVIER B, ALGABA F, SALVADOR J, VICENTE J. Primary bladder carcinoma in situ: assessement of early BCG response as a prognostic factor. Eur. Urol., 1998; 33: 457-463.
126. ALI-el-DEIN B, SARHAN O, HINEV A, IBRAHIEM EL-HI, NABEEH A, GHONEIM M.A. Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index. BJU. Int., 2003; 92: 393-399.
127. HERR H.W, DALBAGNI G. Defining bacillus Calmette-Guérin refractory superficial bladder tumors. J. Urol., 2003; 169: 1706-1708.
128. HERR H.W, SOGANI P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors. J. Urol., 2001; 166: 1296-1299.
129. DALBAGNI G, RECHTSCHAFFEN T, HERR H.W. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to Bacillus Calmette-Guérin therapy?. J. Urol., 1999; 162: 708-709.
130. SKEMP N.M, FERNANDES E.T. Routine bladder biopsy after Bacille Calmette-Guérin treatment: is it necessary?. Urology.? Urology., 2002; 162: 224-226
131. HIGHSHAW R.A, TANAKA S.T, EVANS C.P, deVERE WHITE R.W. Is bladder biopsy necessary at three or six months post BCG therapy?. Urologic. Oncology., 2003; 21: 207-209.
132. ZERBIB M., BOUCHOT O. Rapport du congrès 2002 de l'Association Française d'Urologie Progrès en Urologie.,Vol 12 nov. 2002 no5.
133. Comité de Cancérologie de l'Association Française d'Urologie. Recommandations 2002 Progrès en Urologie 12.,no5., Supp2'
134. GHONEIM., M. A El-MEKRECH., M., EL-BAZ M A., EL-ATTAR I A and ASHAMALLAH A : Radical cystectomy for carcinoma of the bladder : critical evaluation of the result in 1026 cases. J Urol 158., 393.,1997
135. HAUTMANN RE., de PETRICIONNI R., GOTTFRIED HW., KLEINSCHMIDT K., MATTOS R.,PAROS T. The ileal neobladder:complications and functional results in 363 patients after 11 years of follow-up;J.Urol.,1999 161 2 422.
136. HERR H., I LEE C., CHANG S., and LERNER S., for the Bladder Cancer Cooperative Group. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer : a collaborative group report. J. Urol vol 171., 1823-1828;May 2004.
137. HERR H.W.: Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology.,61:105., 2003.
138. LEBRET T., HERVE JM., YONNEAU L., BARRE P., LUGAGNE PM., BUTREAU M., MOLINIE V., BOTTOH :Etude de la survie après cystectomie pour cancer de vessie. A propos de 504 cas Prog Urol., 2000.,10 553-560.
139. STEIN J., LIESKOVSKI., G., COTE R., GROSHEN S., FENG A C., BOYD S., SKINNER E., and all.: Radical cystectomy in the treatment of invasive bladder cancer: long -term results in 1054 patients. J Clin Oncol 2001, 19, 666-6675.
140. YIOU R., PATARD J.J., BENHARD H., ABBOU C C.,CHOPIN D K.,:Outcome of radical cystectomy for bladder cancer according to the disease at presentation. BJU Int.,2002.,89:374 378.
141. ZERBIB M., THIROUARD D., CONQUY S., THIOUN., N FLAM., T DEBRE B. Evolution des techniques et des résultats des cystectomies à visée curative pour cancer de la vessie. A propos de 106 cas. Cancer Radiother., 1998., 2: 505-511.
142. GRANT D., TAYLOR., DAVID A DUCHENE and KOENEMAN K.S: Hand assisted laparoscopic cystectomy with mililaparotomt ileal conduit: series report and comparison with open cystectomy.J.Urol;., Vol.172., 1291-1296 October 2004
143. GUPTA NP., GILLI., I FERGANY A., and NAHIi G. Laparoscopic radical cystectomy with intracorporeal ileal conduit diversion :five cases with a 2-year follow-up.BJU Int. 90 391 2002.
144. CATHELINEAU X, ARROYO C, ROZET F, BARRET E, VALLANCIEN G. Laparoscopic assisted radical cystectomy: the montsouris experience after 84 cases. Eur Urol. 2005 Jun;47(6):780-4.
145. GROSSMAN HB, NATALE RB, TANGEN CM, SPEIGHTS VO, VOGEL-ZANG NJ, TRUMP DL, DE VERE WHITE RW, SAROSDY MF, WOOD DP Jr, RAGHAVAN D, CRAWFORD ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28;349(9):859-66.
146. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003 Jun 7;361(9373):1927-34.
147. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis of individual patient data Advanced Bladder Cancer (ABC) Metaanalysis Collaboration. Eur Urol. 2005 Aug;48(2):189-201.
148. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005 Aug;48(2):202-6.
149. HERR HW, DOTAN Z, DONAT SM, BAJORIN DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007 Feb;177(2):437-43.
150. STERNBERG CN, DONAT SM, BELLMUNT J, MILLIKAN RE, STADLER W, DE MLDER P, SHERIF A, VON DER MAASE H, TSUKAMOTO T, SOLOWAY MS. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007 Jan;69(1 Suppl):62-79.
151. SKINNER DG, DANIELS JR, RUSSELL CA, LIESKOVSKY G, BOYD SD, NICHOLS P, KERN W, SAKAMOTO J, KRAILO M, GROSHEN S. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial.J Urol. 1991 Mar;145(3):459-67.
152. LEHMANN J, FRANZARING L, THUROFF J, WELLEK S, STOCKLE M. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int. 2006 Jan;97(1):42-7.
153. LEISSNER J., GHONEIM. M A.,ABOL-ENEIM H., THUROFFJ.W., and all : Extended radical lymphadenectomy in patients with urothelial bladder cancer : result of a prospective multicenter study. J Urol Vol. 171. 138-144., January 2004.
154. HERR HW, BOCHNER BH, DALBAGNI G, DONAT SM, REUTER VE, BAJORIN DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002 Mar;167(3):1295-8.
155. KONETY BR, JOSLYN SA, O'DONNELL MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol. 2003 Mar;169(3):946-50.
156. STEIN JP, SKINNER DG. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol Clin North Am. 2005 May;32(2):187-97.
157. MILLS RD, FLEISCHMANN A, STUDER UE. Radical cystectomy with an extended pelvic lymphadenectomy: rationale and results.Surg Oncol Clin N Am. 2007 Jan;16(1):233-45.
158. LEBRET T., HERVE JM., BARRE P., GAUDEZ F., LUGAGNE PM., BARBAGELATTA M., BOTTO H. Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy. Eur Urol. 1998;33(2):170-4.
159. BELL CR., GUIROL S., COLLINS and all.: The fate of the urethra after definitive treatment of invasive TCC of the urinary bladder BJU Int 83: 607., 1999.
160. CLARK P., STEIN J.,P.,.GROSHEN S.,G., MIRANDA G., CAI J., LIESKOVSKY G., and SKINNER D: The management of urethral transitionnal cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol., Vol 171 1342 _1347.,October 2004.
161. HASSAN JM., COOKSON MS., SMITH J A Jr and CHANG S S, Urethral recurrence in patient following orthototopic Urinary diversion.J Urol., Vol 172., 1338-1341 October 2004.
162. ALI-EL-DEIN B., ABDEL LATIF M., IBRAHIM ERAKY., ATALLAH AS., TAHA N and GHONEIM AM. Secondary malignant involvement of gynecologic organs in radical cystectomy specimens in women: is it mandatory to remove these organs routinely? J.Urol Vol. 172 885-887 Sept.
163. MEINHARDT W., HORENBLAS S. Sexuality preserving cystectomy and neo-bladder: functionnal results of a neo-bladder anastomosed to the prostate. Eur.Urol.2003 43 646-650
164. NGNINKEN BN., LORGE F., MOULIN P., JAMART J., VAN CANGH P. Transitional cell carcinoma involving the prostate. A clinico-pathological retrospective study of 76 cases. J Urol 2003 169 149-152.
165. PLANTE P., LESOURD A., BLANCHET P., CASTAGNOLA C., COLOBY P., DAFFER N., DAVIN JL., DESGRANDCHAMPS F., IRANIJ., MARECHAL JM., MOTTET N., PARIENTE JL. Peut on conserver la coque prostatique au cours des cystectomies pour tumeur de vessie: étude de l'atteinte uretrale et prostatique sur les pièces de cystectomies.
166. SAIDI A., NAHON O.,DANIEL L., LAY F., LECHEVALLIER E., COULANGE C., :Cystectomie et conservation prostatique: résultats fonctionnels et carcinologiques à long terme. A propos de 25 cas. Progrès en Urologie (2004).,14.,172-177.
167. SEBE P., TRAXER O., CUSSENOT O.,HAABF.,THIBAULT P., GATTEGNO B.: Cystectomie avec conservation prostatique dans le traitement des tumeurs de vessie : bases anatomiques.,techniques chirurgicales., indications et résultats. Prog. Urol. ,2003 ;13 1279-1285.
168. VALLANCIEN G.,El FETTOUAH. A., CATHELINEAU X., BAUMERT H.,FROMONT G., GUILLONNEAU B., Cystectomy with prostate sparring for bladder cancer in 100 patients. 10 years of experience. J Urol 2002 168 2413-2417.
169. STARZL A., DRAXEL H., POSCH B., and all.: Risque de tumeur urètrale chez les femmes atteintes de cancer de vessie. L'urètre peut il être conservé afin de réaliser une entérocystoplastie. J Urol 1995 153/950.
170. COLOBY P. Remplacement de vessie chez la femme après cystectomie pour cancer de vessie Prog. Urol 1998 9 41.
171. HAUTMANN R., PAISS T., de PETRICIONNI R. Ileocystoplastie de remplacement chez la femme :9 ans d'expérience J Urol 1996 155 : 76.
172. CHRETIEN Y., MEJEAN A., DURDUX C DUFOUR B., HOUSSET M: Cancer infiltrant de vessie : la radio chimiothérapie peut elle être une alternative à la cystectomie ? J Urol(Paris) 1996.,102.;3-8.
173. HERR HW., BAJONIN., DF., SCHERR HL. Neoadjuvant chemotherapy and bladder sparring surgery for invasion bladder tumor : ten years of out come. J Clin Oncol 1998. 16 1298 1301.
174. ABRATT RP., WILSON JA., PONTIN AR BARNES RD. Salvage cystectomie after radical irradiation for bladder cancer prognostic factors and complications. Br J Urol 1993; 72(5Pt2) 756-760.
175. HOLZBEIERLEIN J., LOPEZ-CORONA E., BOCHNER H.B., HERR W.H.,and all:Partial cystectomy: a contemporary review of the Memorial Sloan Kettering Cancer Center experience and recommendations for patient selection. J.Urol Vol. 172(3)., 878-81 September 2004.
176. NOVICKAC., STEWARTt BH. Partial cystectomy in the treatment of primary and secondary carcinoma of the bladder. J Urol 1976;116:570.
177. SKINNER DG., LIESKOVSKY G. Management of invasive high-grade bladder cancer. In: Skinner DG., Lieskovsky G., eds. Diagnosis and management of genitourinary cancer., vol. 1. Philadelphia: WB Saunders., 1988:295.
178. SOLSONA E..IBORRA I., RICCOS JV.MONROSJL., CASANOVA J., CALABUIC.,C. Feasibility of transurethral resection for muscle infiltration carcinoma of the bladder : long term follow-up of a prospective study. J Urol 1998 ;159(1):95-98.
179. KASSOUF W, SWANSON D, KAMAT AM, LEIBOVICI D, SIEFKERRADTKE A, Munsell MF, Grossmabladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006 Jun;175(6):2058-62
180. HERR HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome.J Clin Oncol. 2001 Jan 1;19(1):89-93.
181. FOSSASD., AASS N., OUS S., WAEHRE H., ILNER K., HANNISDAL E., Survival after curative treatment of muscle invasion blader cancer Acta Oncol 1996 ;35 (Suppl 8) (59-65)
182. ZIETMAN AL., SHIPPLEY WV., KAUHMAN.,DS. Organ conserving approaches to muscle-invasive bladder cancer :future alternatives to radical cystectomie. Ann Med 2000 32. 34-42.
183. VIEWEG J., WHITMORE WF., Jr., HERR HW., SOGANI PC., RUSSO P., SHEINFELD J., FAIR WR. The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience. Cancer. 1994;73(12) : 3020.
184. LEBRET T., HERVE JM., YONNEAU L., MOLINIE V., BARRE P., LUGAGNE PM., BUTREAU M., MIGNOT L., BOTTO H. After cystectomy., is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer? Eur Urol. 2002;42(4):344-9; discussion 3498.
185. STEIN JP., ESRIG D., FREEMAN JA., GROSSFELD GD., GINSBERG DA., COTE RJ., GROSHEN S., BOYD SD., LIESKOVSKY G., SKINNER DG. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology. 1998;51(6):951-5.
186. BULBUL MA., WAZZAN W., NASR R., HEMADY K. The value of cystos-copy., prostate biopsy and frozen-section urethral biopsy prior to orthotopic neobladder substitution. Can J Urol. 2001 ;8(3): 1290-2.
187. JOHNSON DE., WISHNOW KI., TENNEY D. Are frozen-section examinations of ureteral margins required for all patients undergoing radical cystectomy for bladder cancer? Urology. 1989;33(6):451-4.
188. SILVER DA., STROUMBAKIS N., RUSSO P., FAIR WR., HERR HW. Ureteral carcinoma in situ at radical cystectomy: does the margin matter? J Urol. 1997;158(3 Pt 1):768-71..
189. SCHOENBERG MP., CARTER HB., EPSTEIN JI. Ureteral frozen section analysis during cystectomy: a reassessment. J Urol. 1996; 155(4): 1218-20.
190. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol., 2005, 48, 189-199.
191. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol., 2005, 48. 202-205.
192. ABDEL-LATIF, M., ABOL-ENEIN, H., EL BAZ, M., GHONEIM, M. A.: Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J. Urol., 2004, 172, 85-89.
193. BAMIAS, A., ARAVANTINOS, G., DELIVELIOTIS, C., BAFALOUKOS, D., KALOFONOS, C., XIROS, N., ZERVAS, A., MITROPOULOS, D., SAMANTAS, E., PECTASIDES, D., PAPAKOSTAS, P., GIKA, D., KOUROUSIS, C., KOUTRAS, A., PAPADIMITRIOU, C., BAMIAS, C., KOSMIDIS, P., DIMOPOULOS, M. A.: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J. Clin. Oncol., 2004, 22, 220-228.
194. BELLMUNT, J., RIBAS, A., ERES, N., ALBANELL, J., ALMANZA, C., BERMEJO, B., SOLE, L. A., BASELGA, J.: Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer., 1997, 80, 1966-1972.
195. BOCHNER, B. H., CHO, D., HERR, H. W., DONAT, M., KATTAN, M. W., DALBAGNI, G.: Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J. Urol., 2004,172, 1286-1290.
196. BOCHNER, B. H., KATTAN, M. W., VORA, K. C.: Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J. Clin. Oncol., 2006, 20;24, 3967-3972.
197. BOURGUET, P., PLANCHAMP, F., MONTRAVERS, F., VINCENDEAU, S.: [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers]. Prog. Urol., 2007, 17, 172-175.
198. CHAUVET, B., DAVIN, J. L., ALFONSI, M., BERGER, C., VINCENT, P., REBOUL, E: [Conservative treatment of bladder cancers with radiotherapy and concurrent chemotherapy: results and perspectives]., 1998 Cancer Radiother. 2, 499-504.
199. DESERNO, W. M., HARISINGHANI, M. G., TAUPITZ, M., JAGER, G. J., WITJES, J. A., MULDERS, P. F., HULSBERGEN VAN DE KAA CA, KAUFMANN, D., BARENTSZ, J. O.: Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology., 2004 233, 449-456.
200. GEORGE, L., BLADOU, F., BARDOU, V. J., GRAVIS, G., TALLET, A., ALZIEU, C., SERMENT, G., SALEM, N.: Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology., 2004, 64, 488-493.
201. GIRI, P. G., WALSH, J. W., HAZRA, T. A.: Computed tomography in the management of bladder carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 1984, 10, 1121-1125.
202. GROSSMAN, H. B., NATALE, R. B., TANGEN, C. M., SPEIGHTS, V. O., VOGELZANG, N. J., TRUMP, D. L., DEVERE WHITE, R. W., SAROSDY, M. F., WOOD, D. P., Jr., RAGHAVAN, D., CRAWFORD, E. D.: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med., 2003, 349, 859-866.
203. GSCHWEND, J. E., DAHM, P., FAIR, W. R.: Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur. Urol., 2002, 41, 440-448.
204. HAGAN, M. P., WINTER, K. A., KAUFMAN, D. S., WAJSMAN, Z., ZIETMAN, A. L., HENEY, N. M., TOONKEL, L. M., JONES, C. U., ROBERTS, J. D., SHIPLEY, W. U.: RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57, 665-672.
205. HERR, H. W., DONAT, S. M.: Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J. Urol., 2001, 165, 62-64.
206. HERR, H. W., FAULKNER, J. R., GROSSMAN, H. B., NATALE, R. B., DEVERE, W. R., SAROSDY, M. F., CRAWFORD, E. D.: Surgical factors influence bladder cancer outcomes: a cooperative group report. J. Clin. Oncol., 2004, 22, 2781-2789.
207. HOFER, C., KUBLER, H., HARTUNG, R., BREUL, J., AVRIL, N.: Diagnosis and monitoring of urological tumors using positron emission tomography. Eur. Urol., 2001, 40, 481-487.
208. HOUSSET, M., MAULARD, C., CHRETIEN, Y., DUFOUR, B., DELANIAN, S., HUART, J., COLARDELLE, F., BRUNEL, P., BAILLET, F.: Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J. Clin. Oncol., 1993, 11, 2150-2157.
209. KONETY, B. R., DHAWAN, V., ALLAREDDY, V., JOSLYN, S. A.: Impact of malpractice caps on use and outcomes of radical cystectomy for bladder cancer: data from the surveillance, epidemiology, and end results program. J. Urol., 2005, 173, 2085-2089.
210. KONETY, B. R., JOSLYN, S. A.: Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J. Urol., 2003, 170, 1765-1771.
211. KOPPIE, T. M., VICKERS, A. J., VORA, K., DALBAGNI, G., BOCHNER, B. H.: Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer., 2006, 107, 2368-2374.
212. LEBRET, T., HERVE, J. M., YONNEAU, L., MOLINIE, V., BARRE, P., LUGAGNE, P. M., BUTREAU, M., MIGNOT, L., BOTTO, H.: After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer? Eur. Urol., 2002, 42, 344-349.
213. MEAD, G. M., RUSSELL, M., CLARK, P., HARLAND, S. J., HARPER, P. G., COWAN, R., ROBERTS, J. T., USCINSKA, B. M., GRIFFITHS, G. O., PARMAR, M. K.: A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br. J. Cancer., 1998, 78, 1067-1075.
214. MILLS, R. D., TURNER, W. H., FLEISCHMANN, A., MARKWALDER, R., THALMANN, G. N., STUDER, U. E.: Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J. Urol., 2001, 166, 19-23.
215. PAIK, M. L., SCOLIERI, M. J., BROWN, S. L., SPIRNAK, J. P., RESNICK, M. I.: Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J. Urol., 2000, 163, 1693-1696.
216. POULSEN, A. L., HORN, T., STEVEN, K.: Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J. Urol., 1998, 160, 2015-2019.
217. POWLES, T., MURRAY, I., BROCK, C., OLIVER, T., AVRIL, N.: Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur. Urol., 2007, 51, 1511-1520.
218. SHVARTS, O., HAN, K. R., SELTZER, M., PANTUCK, A. J., BELLDEGRUN, A. S.: Positron emission tomography in urologic oncology. Cancer Control., 2002, 9, 335-342.
219. SKINNER, D. G.: Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J. Urol., 1982, 128, 34-36.
220. STEIN, J. P., CAI, J., GROSHEN, S., SKINNER, D. G.: Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J. Urol., 2003, 170, 35-41.
221. STEIN, J. P., SKINNER, D. G.: The role of lymphadenectomy in high-grade invasive bladder cancer. Urol. Clin. North Am., 2005, 32, 187-197.
222. STERNBERG, C. N., DE MULDER, P., SCHORNAGEL, J. H., THEODORE, C., FOSSA, S. D., VAN OOSTEROM, A. T., WITJES, J. A., SPINA, M., VAN GROENINGEN, C. J., DUCLOS, B., ROBERTS, J. T., DE BALINCOURT, C., COLLETTE, L.; Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer., 2006, 42, 50-54.
223. STERNBERG, C. N., YAGODA, A., SCHER, H. I., WATSON, R. C., HERR, H. W., MORSE, M. J., SOGANI, P. C., VAUGHAN, E. D., Jr., BANDER, N., WEISELBERG, L. R.,.: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol., 1988, 139, 461-469.
224. VON DER, M. H., HANSEN, S. W., ROBERTS, J. T., DOGLIOTTI, L., OLIVER, T., MOORE, M. J., BODROGI, I., ALBERS, P., KNUTH, A., LIPPERT, C. M., KERBRAT, P., SANCHEZ, R. P., WERSALL, P., CLEALL, S. P., ROYCHOWDHURY, D. F., TOMLIN, I., VISSERENGRUL, C. M., CONTE, P. F.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol., 2000, 18, 3068-3077.
225. WINQUIST, E., KIRCHNER, T. S., SEGAL, R., CHIN, J., LUKKA, H.: Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis., 2004, J. Urol. 171, 561-569.
226. WOOD, D. P., Jr., LORIG, R., PONTES, J. E., MONTIE, J. E.: The role of magnetic resonance imaging in the staging of bladder carcinoma. J. Urol., 1988, 140, 741-744.
227. ZEBIC, N., WEINKNECHT, S., KROEPFL, D.: Radical cystectomy in patients aged > or = 75 years: an updated review of patients treated with curative and palliative intent. BJU. Int., 2005, 95, 1211-1214.
228. STEIN JP, SKINNER DG. : Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006 ;24:296-304.
229. DEVITA, HELLMAN, AND ROSENBERG'S Cancer: Principles and Practice of Oncology, Seventh Edition
230. BELLMUNT J, ALBANELL J, PAZ-ARES L, CLIMENT MA, GONZALEZ-LARRIBA JL, CARLES J, DE LA CRUZ JJ, GUILLEM V, DIAZRUBIO E, CORTES-FUNES H, BASELGA J.: Spanish Oncology Genitourinary Group Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002 Aug 15;95(4):751-7.
231. FOSSA SD, STERNBERG C., SCHER HI, THEODORE CH, MEAD B, DEARNALEY D, ROBERTS JT, SKOVLUND E.: Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.Br J Cancer. 1996 ;74:1655-1659
232. STERNBERG CN, DE MULDER P, SCHORNAGEL JH et al.Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006 ;42:50-54
233. VON DER MAASE H, HANSEN SW, ROBERTS Jt et aL Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.J Clin Oncol. 2000 ;18:3068-3077
234. DREICER R, MANOLA J, ROTH BJ et al, Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.Cancer. 2004 15;100:1639-1645
235. BAMIAS A, ARAVANTINOS G, DELIVELIOTIS C et al.: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. Clin Oncol. 2004 Jan 15;22(2):220
236. (REF ASCO 2007 BELLMUNT Abstract 5030)
237. BAMIAS A, MOULOPOULOS LA, KOUTRAS A et al.The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.Cancer. 2006 15;106:297-303
238. VAUGHN DJ, MANOLA J, DREICER R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group.Cancer. 2002 Sep 1;95:1022-1027.
239. CARLES J, ESTEBAN E, CLIMENT Met al.Gemcitabine and oxaliplatin combination: a multicenter phase II in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol. 2007 ;18:1359-1362
240. THEODORE C., BIDAULT F, BOUVEAU-FORTET N et al. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.Ann Oncol. 2006 Jun;17:990-994
241. HUSBAND JE, SCHWARTZ LH, SPENCER J,et al..: International Cancer Imaging Society.Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer. 2004 Jun 14;90(12):2256-60.
242. ALBERS P, SIENER R, HARTLEIN M, FALLAHIM, HAEUTLE D, PERABO FG, STEINER G, BLATTER J, MULLER SC.: German TCC Study Group of the German Association of Urologic Oncology. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life.Onkologie. 2002 Feb;25(1):47-52
243. VAISHAMPAYAN UN, FAULKNER JR, SMALL EJ et al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.Cancer. 2005 15;104:1627-1632
244. STERNBERG CN, CALABRO F, PIZZOCARO G et al.Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.Cancer. 2001 15;92:2993-2998.
245. DE MULDER PH, THEODORE C., SELLA A, KORIAKINE O, STERNBERG CN, COLLETTE L, DE BALINCOURT C. Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract.Ann Oncol. 2000 Nov;11(11):1391-4
246. PECTIASIDES D, ARAVANTINOS G, KALOFONOS H et al.Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2001 Oct;12(10):1417-1422.
247. BELLMUNT J, COS J, CLERIES R, et al.: Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 2002;20(5-6):673-85
248. CULINE S, THEODORE C, DE SANTIS M et al.A phase II study of vinflunine in bladder cancer patients progressing after first-line platinumcontaining regimen.Br J Cancer. 2006;94:1395-1401
249. Glatsky MD, Mironov S, lanosos A et al.: Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.Invest New Drugs. 2007 Jun;25(3):265-70
250. HUSSAIN MH, MC VICTOR GR, PETRYLAK DP et al.: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.J Clin Oncol. 2007 1;25:2218-2224.
251. JIN Y, IWATA KK, BELLDEGRUN A et al. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.Mol Cancer Ther. 2006 ;5:1754-1763
252. SIEFKER-RADTKE AO, WALSH GL,PISTERS LL et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience.J Urol. 2004 ;171:145-148.
253. HERR HW, DONAT SM, BAJORIN DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer, J Urol 2001;165:811-814,
254. VAKAET LA, BOTERBERG T. Pain control by ionizing radiation of bone metastasis. Int J Dev Biol. 2004;48(5-6):599-606
255. SEAMAN EK, SLAWIN KM, BENSON MC. : Treatment options for upper tract transitional-cell carcinoma. Urol Clin North Am 1993;20:349-54
256. GERBER GS, LYON ES.: Endourological management of upper tract urothelial tumors. J Urol 1993;150:2-7
257. SECIN FP, KOPPIE TM, SALAMANCA JI, BOKHARI S, RAJ GV, OLGAC S, SERIO A, VICKERS A, BOCHNER BH.: Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. Int J Urol. 2007; 14:26-32.
258. LEHMANN J, SUTTMANN H, KOVAC I, HACK M, KAMRADT J, SIEMER S, WULLICH B, ZWERGEL U, STOCKLE M.: Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol. 2007; 51:1281-8.
259. ROUPRET M, HUPERTAN V, TRAXER O, LOISON G, CHARTIERKASTLER E, CONORT P, BITKER MO, GATTEGNO B, RICHARD F, CUSSENOT O.: Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology. 2006; 67 :1181-7.
260. ZINCKE H, NEVES RJ.: Feasibility of conservative surgery for transitional cell cancer of the upper urinary tract. Urol Clin North Am 1984;11:717-24
261. FUJIMOTO N, SATO H, MIZOKAMI A, INATOMI H, MATSUMOTO T.: Results of conservative treatment of upper urinary tract transitional cell carcinoma. Int J Urol 1999;6:381-7
262. IBORRA I, SOLSONA E, CASANOVA J, RICOS JV, RUBIO J, CLIMENT MA. : Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J Urol 2003;169:82-5
263. LIATSIKOS EN, DINLENC CZ, KAPOOR R, SMITH AD.: Transitionalcell carcinoma of the renal pelvis: ureteroscopic and percutaneous approach. J Endourol 2001;15:377-83
264. MURPHY DM, ZINCKE H, FURLOW WL.: Primary grade 1 transitional cell carcinoma of the renal pelvis and ureter. J Urol 1980;123:629-31
265. MURPHY DM, ZINCKE H, FURLOW WL.: Management of high grade transitional cell cancer of the upper urinary tract. J Urol 1981;125:25-9
266. ZUNGRI E, CHECHILE G, ALGABA F, DIAZ I, VILA R CASTRO C.: Treatment of transitional cell carcinoma of the ureter: is the controversy justified? Eur Urol 1990;17:276-80
267. CHARBIT L, GENDREAU MC, MEE S, CUKIER J.: Tumors of the upper urinary tract: 10 years of experience. J Urol 1991;146:1243-6
268. MUFTI GR, GOVE JR, BADENOCH DF, FOWLER CG, TIPTAFT RC ENGLAND HR, PARIS AM, SINGH M, HALL MH, BLANDY JP.: Transitional cell carcinoma of the renal pelvis and ureter. Br J Urol 1989;63:135-40
269. BABAIAN RJ, JOHNSON DE. : Primary carcinoma of the ureter. J Urol 1980;123(3):357-9
270. MAZEMAN E. Tumours of the upper urinary tract calyces, renal pelvis and ureter. Eur Urol 1976;2:120-6
271. STRONG DW, PEARSE HD: Recurrent urothelial tumors following surgery for transitional cell carcinoma of the upper urinary tract. Cancer 1976;38:2173-83
272. FUCHS GJ. A coming of age-percutaneous endopyelotomy and a technique to watch out for, that is ureteroscopic surgery for upper tract transitional cell carcinoma. J Urol 1997;157:1620-1
273. MARTINEZ-PINEIRO JA, GARCIA MATRES MJ, MARTINEZ-PINEIRO L.: Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol 1996;156:377-85
274. JABBOUR ME, SMITH AD.: Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am 2000;27:739-50
275. KEELEY FX JR, BIBBO M, BAGLEY DH: Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol 1997;157:1560-5
276. BAGLEY DH.: Ureteroscopic laser treatment of upper urinary tract tumors. J Clin Laser Med Surg 1998;16:55-9
277. ELLIOTT DS, BLUTE ML, PATTERSON DE, BERGSTRALH EJ, SEGURA JW.: Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology 1996;47:819-25
278. ELLIOTT DS, SEGURA JW, LIGHTNER D, PATTERSON DE, BLUTE ML.: Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology 2001;58:174-8
279. CLARK PE, STREEM SB, GEISINGER MA.: 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol 1999;161:772-5
280. JABBOUR ME, DESGRANDCHAMPS F, CAZIN S, TEILLAC P, LE DUC A, SMITH AD.: Percutaneous management of grade II upper urinary tract transitional cell carcinoma: the long-term outcome. J Urol 2000;163:1105-7
281. LEE BR, JABBOUR ME, MARSHALL FF, SMITH AD, JARRETT TW.: 13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: equivalent outcomes. J Endourol 1999;13:289-94
282. HUANG A, LOW RK, DEVERE WHITE R: Nephrostomy tract tumor seeding following percutaneous manipulation of a ureteral carcinoma, J Urol 1995;153:1041-2
283. SHARMA NK, NICOLA, POWELL CS.: Track infiltration following percutaneous resection of renal pelvic transitional cell carcinoma. Br J Urol 1994;73:597-8
284. SENGUPTA S, HAREWOOD L.: Transitional cell carcinoma growing along an indwelling nephrostomy tube track. Br J Urol 1998;82:591
285. PLANCKE HR, STRIJBOS WE, DELAERE KP: Percutaneous endoscopic treatment of urothelial tumours of the renal pelvis. Br J Urol 1995;75:7369
286. CHEN GL, BAGLEY DH: Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 2000;164:1173-6
287. GRASSO M, FRAIMAN M, LEVINE M.: Ureteropyeloscopic diagnosis and treatment of upper urinary tract urothelial malignancies. Urology 1999;54:240-6
288. LIM DJ, SHATTUCK MC, COOK WA.: Pyelovenous lymphatic migration of transitional cell carcinoma following flexible ureterorenoscopy. J Urol 1993;149:109-11
289. HERR HW: Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin. J Urol 1985;134:531-2
290. STUDER UE, CASANOVA G, KRAFT R, ZINGG EJ: Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ. J Urol 1989;142:975-7
291. RAMSEY JC, SOLOWAY MS: Instillation of bacillus Calmette-Guerin into the renal pelvis of a solitary kidney for the treatment of transitional cell carcinoma. J Urol 1990;143:1220-2
292. SCHOENBERG MP, VAN ARSDALEN KN, WEIN AJ: The management of transitional cell carcinoma in solitary renal units. J Urol 1991;146:700-2
293. OKUBO K: Intrarenal BCG therapy for carcinoma in situ of the upper urinary tract: long term follow-up and natural course in cases of failure. BJU Int 2001, 88:343-347
294. THALMANN GN, MARKWALDER R, WALTER B, STUDER UE. Longterm experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 2002;168:1381-5
295. SHARPE JR, DUFFY G, CHIN JL: Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ. J Urol 1993;149:457-9;
296. BELLMAN GC, SWEETSER P, SMITH AD: Complications of intracavitary bacillus Calmette-Guerin after percutaneous resection of upper tract transitional cell carcinoma. J Urol 1994;151:13-5
297. BASSI P, IAFRATE M, LONGO F, IANNELLO A, MOSTACCIO G, INGRASSIA A, REPELE M, TAVOLINIIM.: Intracavitary therapy of noninvasive transitional cell carcinomas of the upper urinary tract. A review of the literature. Urol Int 2001;67:189-94
298. HAYASHIDA Y, NOMATA K, NOGUCHI M, EGUCHI J, KOGA S, YAMASHITA S, HAYASHI M, KANATAKE H.Long-term effects of bacille Calmette-Guerin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology. 2004; 63: 1084-8.
299. SCHNAPP DS, WEISS GH, SMITH AD: Fever following intracavitary bacillus Calmette-Guerin therapy for upper tract transitional cell carcinoma. J Urol 1996 Aug;156:386-8
300. TAVOLINI IM, GARDIMAN M, BENEDETTO G, BASSI P.: Unmanageable fever and granulomatous renal mass after intracavitary upper urinary tract bacillus Calmette-Guerin therapy. J Urol 2002;167:244-5
301. YOKOGI H, WADA Y, MIZUTANI M, IGAWA M, ISHIBE T: Bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. Br J Urol 1996;77:676-9
302. PATEL A, FUCHS GJ: New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol 1998;159:71-5
303. NONOMURA N, ONO Y, NOZAWA M, FUKUI T, HARADA Y, NISHIMURA K, TAKAHA N, TAKAHARA S, OKUYAMA A: Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol 2000;38:701-4
304. NISHINO Y, YAMAMOTO N, KOMEDA H, TAKAHASHIY, DEGUCHI T: Bacillus Calmette-Guerin instillation treatment for carcinoma in situ of the upper urinary tract. BJU Int 2000;85:799-801
305. SMITH AY, VITALE PJ, LOWE BA, WOODSIDE JR.: Treatment of superficial papillary transitional cell carcinoma of the ureter by vesicoureteral reflux of mitomycin C. J Urol 1987;138:1231-3
306. EASTHAM JA, HUFFMAN JL.: Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors. J Urol 1993;150:324-5
307. KEELEY FX JR, BAGLEY DH.: Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol 1997;158:2074-7
308. LAM JS, GUPTA M.: Ureteroscopic management of upper tract transitional cell carcinoma. Urol Clin North Am. 2004;31:115-28.
309. ROUPRET M, TRAXER O, TLIGUI M, CONORT P, CHARTIER-KASTLER E, RICHARD F, et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol, 2007;51:709-13;
310. ROUPRET M, HARMON JD, SANDERSON KM, BARRET E, CATHELINEAU X, VALLANCIEN G, et al. Laparoscopic distal ureterectomy and anastomosis for management of low-risk upper urinary tract transitional cell carcinoma: preliminary results. BJU Int, 2007; 99: 623-7.
311. MANABE D, SAIKA T, EBARA S, UEHARA S, NAGAI A, FUJITA R, IRIE S, YAMADA D, TSUSHIMAT, NASU Y, KUMON H.: Comparative study of oncologic outcome of laparoscopic nephroureterectomy and standard nephroureterectomy for upper urinary tract transitional cell carcinoma. Urology. 2007; 69:457-61.
312. OTANIM, IRIE S, TSUJIY.: Port site metastasis after laparoscopic nephrectomy: unsuspected transitional cell carcinoma within a tuberculous atrophic kidney. J Urol. 1999;162:486-7.
313. ONG AM, BHAYANI SB, PAVLOVICH CP.: Trocar site recurrence after laparoscopic nephroureterectomy. J Urol. 2003;170:1301.
314. TSIVIAN A, SIDIAA.: Port site metastases in urological laparoscopic surgery. J Urol. 2003;169:1213-8.
315. RASSWEILER J, TSIVIAN A, KUMAR AV, LYMBERAKIS C, SCHULZE M, SEEMAN O, FREDE T.: Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol. 2003;169:2072-5.
316. MATSUI Y, OHARA H, ICHIOKA K, TERADA N, YOSHIMURA K, TERAI A.: Abdominal wall metastasis after retroperitoneoscopic assisted total nephroureterectomy for renal pelvic cancer. J Urol. 2004; 171:793
317. SIMON SD, FERRIGNI RG, NOVICKI DE, LAMM DL, SWANSON SS, ANDREWS PE.: Mayo Clinic Scottsdale Experience with laparoscopic nephroureterectomy. JSLS. 2004; 8:109-13.
318. ROUPRET M, HUPERTAN V, SANDERSON KM, HARMON JD, CATHELINEAU X, BARRET E, VALLANCIEN G, ROZET : Oncologic control after open or laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: a single center experience. Urology. 2007; 69: 656-61
319. MAULARD-DURDUX C, DUFOUR B, CHRETIEN HY : Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival? J Urol 1996;155:115.
320. OZAHIN M, ZOUHAIR A, VILLA S : Prognostic factors in urothelial renal pelvis and ureter tumours: a multicenter rare cancer network study. Eur J Cancer 1999;35:738.
321. LERNER SE, BLUTE ML, RICHARDSON RL : Platinum based chemotherapy for advanced transitional cell cancer of the upper urinary tract. Mayo Clin Proc 1996:71:945
322. PYCHA A, GRBOVIC M, POSCH B: Paclitaxel and carboplatinum in patients with metastatic transitional cell cancer of the urinary tract. Urology 1999;53:510
323. INQUIST E, KIRCHNER TS, SEGAL R, CHIN J, LUKKA H: Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004, 171: 561-9.
324. THEODORE C, BIDAULT F, BOUVET-FORTEAU N, ABDELATIF M, FIZAZI K, DI PALMA M, WIBAULT P, DE CREVOISIER R, LAPLANCHE A: A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol.